购物车
- 全部删除
- 您的购物车当前为空
LX1作为一种化合物,专门针对雄激素受体(AR)、AR变异体及类固醇合成酶AKR1C3,用于抗前列腺癌治疗。该化合物通过抑制AKR1C3酶活性,阻止雄烯二酮向睾酮的转化,并降低AR及AR-V7的表达,从而下调其靶基因。此外,LX1能够克服肿瘤细胞对Enzalutamide的耐药性,并且与之联合应用时能够进一步抑制肿瘤生长。
LX1作为一种化合物,专门针对雄激素受体(AR)、AR变异体及类固醇合成酶AKR1C3,用于抗前列腺癌治疗。该化合物通过抑制AKR1C3酶活性,阻止雄烯二酮向睾酮的转化,并降低AR及AR-V7的表达,从而下调其靶基因。此外,LX1能够克服肿瘤细胞对Enzalutamide的耐药性,并且与之联合应用时能够进一步抑制肿瘤生长。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | LX1, an anti-prostate cancer compound, specifically targets the androgen receptor (AR), AR variants, and the steroidogenic enzyme AKR1C3. It inhibits AKR1C3's enzymatic function, decreases the conversion of androstenedione to testosterone, and reduces the expression of both AR and AR-V7, subsequently downregulating their target genes. Additionally, LX1 is effective in overcoming tumor cell resistance to Enzalutamide, and when combined with Enzalutamide, it further suppresses tumor growth. |
分子量 | 439.35 |
分子式 | C22H15F6NO2 |
CAS No. | 2647877-84-5 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.